In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Klotho Neuroscience, Inc. Announces an Approach to Increase Longevity and Healthy Life Span - Replace a Silenced Gene Called ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Redefining Performance, Design, and Intelligent Technology for the Next Generation of Electric Vehicles.Powered by ...